Company profile
MiNK Therapeutics, Inc.
INKT · NASDAQ (Clinical-stage iNKT-cell-therapy biopharmaceutical company (NY), spun off from Agenus. Confirmed via Nasdaq/stockanalysis.com/Investing.com: began trading on Nasdaq under ticker INKT on 2021-10-15. Sources: https://clinicaltrials.gov/study/NCT04754100 Entity resolved by asset-pipeline-v2.)
Share price · INKT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Invariant TCR / NKG2D ligands (tumor cell recognition), no singleCell therapy | Multiple Myeloma |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.